HSPB6: A Potential Prognostic Biomarker, Inhibiting the Epithelial–Mesenchymal Transition (EMT) Process Through the PI3K/Akt Signaling Pathway Based on the Machine Learning and Experimental Validation
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Abstract
Bladder cancer (BC) is a prevalent malignant tumor worldwide, posing a significant public health burden and challenge to human society. Current therapeutic modalities for BC include surgical treatment, radiotherapy, chemotherapy, targeted therapy, and immunosuppressive therapy. However, almost all patients experience disease progression and ultimately succumb to BC. Our study demonstrated that elevated expression of Heat Shock Protein Beta‐6 (HSPB6) correlated with higher clinical grades and stages, establishing it as an independent prognostic risk factor for BC. Enrichment analysis indicated that HSPB6 is associated with the extracellular matrix in BC. Experimental validation revealed that HSPB6 overexpression inhibits the proliferation of BC cell line T24. This effect may be achieved by inhibiting the PI3K/Akt signaling pathway, which in turn leads to inhibition of epithelial–mesenchymal transition (EMT). Furthermore, we developed a prognostic risk model that incorporated DDR2, DPYSL3, MFAP5, PDGFRB, and SPOCD1, allowing accurate prediction of patient outcomes based on immunological status. In conclusion, this study highlights that HSPB6 overexpression can restrain the proliferation of BC cells and inhibit EMT, underscoring its potential as a diagnostic marker and therapeutic target in BC.Keywords
This publication has 45 references indexed in Scilit:
- T1 bladder cancer: current considerations for diagnosis and managementNature Reviews Urology, 2018
- Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in CancerCurrent Drug Targets, 2018
- Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and OutcomesEuropean Urology, 2016
- Upregulation of Heat Shock Proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in Tumour Tissues Is Associated with Poor Outcomes from HBV-Related Early-Stage Hepatocellular CarcinomaInternational Journal of Medical Sciences, 2015
- Targeting EMT in cancer: opportunities for pharmacological interventionTrends in Pharmacological Sciences, 2014
- Tetrachloroethylene Exposure and Bladder Cancer Risk: A Meta-Analysis of Dry-Cleaning-Worker StudiesEnvironmental Health Perspectives, 2014
- Heat shock protein B6 potently increases non-small cell lung cancer growthMolecular Medicine Reports, 2014
- Small heat shock protein 20 (HspB6) in cardiac hypertrophy and failureJournal of Molecular and Cellular Cardiology, 2011
- The small heat shock protein, HSPB6, in muscle function and diseaseCell Stress and Chaperones, 2010
- Bladder cancer: Epidemiology, staging and grading, and diagnosisUrology, 2005